NCT05675410 2026-03-19
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI)
Phase 3 Recruiting
National Cancer Institute (NCI)
Suzhou BlueHorse Therapeutics Co., Ltd.
Advenchen Laboratories, LLC
University College, London
Swiss Cancer Institute
Shanghai Juncell Therapeutics
National Medical Research Radiological Centre of the Ministry of Health of Russia
University of Miami
Institut Bergonié
Linnaeus Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center